Viral Genetics’ Subsidiary, VG Energy, Commencing Sales of LipidMax™

Posted: September 11, 2012 at 9:13 pm

SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics (VRAL) majority-owned subsidiary, VG Energy, has contracted with Eno Research Chemicals & Custom Synthesis Group for production of its LipidMax lipid enhancement compound, in sufficient capacity to meet demand from commercial and research end-users worldwide.

Orders for LipidMax can be placed at https://store.vgenergy.net/. Once approved for purchases, customers will be shipped LipidMax in 10g units. Additional information is also available at lipidmax@vgenergy.net.

LipidMax, the first product marketed by VG Energy, is a lipid-enhancement compound for use in the production of oils from algae, corn, palm, and other plants or plant-like organisms and is based on the Companys exclusively licensed Metabolic Disruption Technology (MDT).

Independent testing has shown that, when treated with LipidMax, the yields from several algae and algae-like species including Schizochytrium, Prymnesium parvum, and Chlamydomonas reinhardtii, have shown significant increases in oil (lipid) yields. Similar, if not stronger, results have been observed in palm and other oil-producing plants. The Company believes that LipidMax should generate oil-enhancing results in most other species of plants and plant-like organisms beyond those mentioned, and is continuing testing to validate and quantify this.

The oil yield increase is thought to provide a possible catalyst for changing the economic feasibility for algal-derived biofuels in the marketplace, making biofuels more cost-competitive, when compared to petroleum-based fuels. Similar cost-reduction effects in plant oils used as food, nutraceuticals and cosmetics should also result from productivity-enhancement.

The company joins a newly emerging category of businesses called intermediates1 in the biofuels and bio-chemical sectors. These products can be utilized in the production of an array of fuels, chemicals, flavors, fragrances and other end products. Intermediates constitute building blocks and intermediate steps upon which other processes and products are built, and as such can become integral to building the value chain in these rapidly growing bio-based industries.

VG Energys Chief Scientist, Dr. M. Karen Newell-Rogers, noted that the Eno Research Chemicals and Custom Synthesis Group is fully cGMP- and cGLP-compliant, has passed a rigorous set of internal testing protocols, and the product produced at the facility meets the companys standards for chemical consistency, purity and yield. When scaled up to commercially viable quantities, the LipidMax produced at this facility meets or exceeds the same quality standards we established using smaller research-grade batches at the Agrilife facilities. The process of commercial or industrial scale-up of a chemical such as our product can sometimes alter the ultimate activity of a compound, but LipidMax produced at scaled up production protocols has shown to match the results we observed during initial evaluations.

Haig Keledjian, Viral Genetics CEO said, This marks the transition to commercialization from a purely research based company and we are very pleased and excited to now commence sales of our LipidMax product to customers in the bio-fuels, and high quality edible and nutraceutical oil markets.

Mr. Keledjian continued, We expect that initial customers will be industrial laboratories and academic research institutions looking to establish and verify the economic advantages of LipidMax that we have demonstrated in our own and independent testing. As end users attain increased yields of usable oil in commercial size quantities, we anticipate a rapid and widespread awareness of LipidMax, leading to adoption of LipidMax in a host of industries worldwide including algal biofuel and palm oil, amongst others.

See the original post here:
Viral Genetics’ Subsidiary, VG Energy, Commencing Sales of LipidMax™

Related Posts

Comments are closed.

Archives